PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
News|Articles|August 14, 2017
ICH Announces Training Program
Author(s)Pharmaceutical Technology Editors
A pilot program will offer instruction on scientific and regulatory guidelines including training on GMPs and quality.
Advertisement
On August 14, 2017, the International Council for Harmonization (ICH) announced a training pilot program that will partner its Training Subcommittee with a group of trainers to provide instruction on ICH scientific and regulatory principles. ICH will evaluate the pilot program at the end of 2017 to determine a longer-term training strategy
The committee performed a needs assessment survey to determine which guidelines needed training. The following training will be provided:
- Intermediate Course for DMF, ASMF, Module 3 Submissions in eCTD Format, Frankfurt, Germany, Nov. 6–7, 2017. ICH will provide more information in the future.
- Intermediate Course for Regulatory Submissions in eCTD Format, San Diego, CA, USA, Oct. 17–18, 2017. ICH will provide more information in the future.
- ICH GCP Training, Cambridge, MA, USA, Oct. 17–19, 2017. The workshop, which will be taught by members of FDA, the European Medicines Agency, and Health Canada, will advance understanding of ICH E6 and the revised E6(R2) guidelines. Information about the program can be found on the
ICH website .
- ICH Q1 Stability Training, Burlington, MA, USA, Oct. 11–13, 2017. The training will help participants understand expectations regarding stability testing. Information about the program can be found on the ICH
website .
- GMP for APIs (ICH Q7) Training, Tokyo, Japan - October 10-11, 2017. This course, run by Japan’s Pharmaceuticals and Medical Devices Agency and the Parenteral Drug Association, will offer insights from GMP inspectors and the requirements of ICH Q7. Information about the program can be found on the ICH
website .
ICH-endorsed programs will include the ICH logo.
Source:
Advertisement
Related to this article
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
Karthik Iyer, Eli Lilly, details an AI system linking GMP findings, audits, and deviations for cited, inspection-ready regulatory intelligence.
At the PDA/FDA Joint Regulatory Conference 2026, Helen Motamen, MS
global head, Sanofi Quality Audit, Inspection, Intelligence & Advocacy, at Sanofi, provided advice for creating a strong internal audit program.
At PDA/FDA Joint Regulatory Conference 2026, PCI Pharma's Bassler details how a QMS overhaul turned an FDA 483 into stronger quality culture.
AI can turn medical device risk management into a continuous signal.
On PharmTech.com this week, coverage of upcoming events continued, experts continued to discuss the use of AI in pharma, and validation in oral solid dosage product production was emphasized.
This article explores the historical use of silicone oil in the performance of primary drug product packaging; design of experiment test results for selection of the cleaning agent and CCPs; assessment of visible residue limits and Fourier-transform infrared spectroscopy surface analysis; and setting health-based exposure limits for silicone oil using a non-uniform distribution model, and a previously published permitted daily exposure.
Advertisement
Advertisement